PERRIGO Co plc

Listed Company

PRGOCIK 0001585364NYSELarge AcceleratedPharmaceutical PreparationsL2IEFY ends Dec 31

Period

FY 2025

Revenue

$4.25B

Net Income

$-1.43B

Total Assets

$8.54B

Equity

$2.94B

Shares Out

137.65M

Op. Cash Flow

$238.50M

Business

Perrigo Company plc is a pure-play self-care company that provides high-quality, nonprescription health and wellness solutions for consumers. It offers a broad portfolio of products including OTC medicines, infant formula, vitamins and supplements, oral care, skin care, women’s health (including OTC contraception), pain and sleep aids, and both store-brand private label and branded products. The company reports under two operating segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). Its products are sold primarily in North America, Europe and Australia through retailers, pharmacies, wholesalers, e-commerce and direct-to-consumer channels.

Summary from filing dated 2025-02-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	4,253	4,373	4,656	4,452	4,139
Cost of sales	2,759	2,831	2,975	2,996	2,723
Gross profit	1,495	1,543	1,680	1,455	1,416
Distribution	93	98	111	113	93
Research and development	95	112	123	123	122
Selling	527	547	642	585	536
Administration	436	468	522	512	482
Impairment charges	1,363	89	90	0	173
Restructuring	72	110	42	43	17
Other operating (income) expense, net	31	6	−800,000	800,000	−418
Total operating expenses	2,617	1,430	1,529	1,377	1,006
Operating income (loss)	−1,122	113	152	79	410
Interest expense, net	163	188	174	156	—
Other (income) expense, net	13	−900,000	−10	53	27
Loss on extinguishment of debt	0	7	−3	9	0
Income (loss) from continuing operations before income taxes	−1,298	−81	−8	−139	259
Income tax expense	104	80	−4	−8	390
Loss from continuing operations	−1,402	−161	−4	−131	−131
Loss from discontinued operations, net of tax	−23	−11	−8	−10	62
Net income (loss)	−1,425	−172	−13	−141	−69
Continuing operations (in dollars per share)	−10.12	−1.17	−0.03	−0.97	−0.98
Discontinued operations (in dollars per share)	−0.17	−0.08	−0.06	−0.07	0.46
Basic earnings (loss) per share (in dollars per share)	−10.29	−1.25	−0.09	−1.04	−0.52
Continuing operations (in dollars per share)	−10.12	−1.17	−0.03	−0.97	−0.98
Discontinued operations (in dollars per share)	−0.17	−0.08	−0.06	−0.07	0.46
Diluted earnings (loss) per share (in dollars per share)	−10.29	−1.25	−0.09	−1.04	−0.52
Basic (in shares)	139	137	135	135	134
Diluted (in shares)	139	137	135	135	134

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	532	559	751	601	1,865
Accounts receivable, net of allowance for credit losses of $6.5 and $7.4, respectively	613	642	740	697	653
Inventories	1,149	1,082	1,141	1,150	1,020
Prepaid expenses and other current assets	231	199	201	272	306
Current assets held for sale	273	0	—	0	16
Total current assets	2,797	2,482	2,833	2,720	3,860
Property, plant and equipment, net	899	918	916	926	864
Operating lease assets	168	175	—	—	—
Goodwill and indefinite-lived intangible assets	2,055	3,325	3,534	3,549	3,005
Definite-lived intangible assets, net	2,352	2,424	2,981	3,230	2,146
Deferred income taxes	3	5	26	7	7
Other non-current assets	262	319	335	368	378
Total non-current assets	5,738	7,166	7,976	8,297	6,566
Total assets	8,535	9,648	10,809	11,017	10,426
Accounts payable	475	495	478	537	411
Payroll and related taxes	112	123	127	136	119
Accrued customer programs	111	133	164	139	126
Other accrued liabilities	231	239	335	—	—
Accrued income taxes	21	17	42	14	17
Current indebtedness	37	36	441	36	604
Current liabilities held for sale	27	0	—	0	33
Total current liabilities	1,013	1,044	1,586	1,114	1,588
Long-term debt, less current portion	3,604	3,582	3,633	4,070	2,917
Deferred income taxes	169	203	262	368	239
Other non-current liabilities	814	499	560	623	530
Total non-current liabilities	4,587	4,284	4,455	5,062	3,686
Total liabilities	5,600	5,328	6,041	6,175	5,274
Contingencies - Refer to Note 20	—	—	—	—	—
Preferred shares, $0.0001 par value per share, 10 shares authorized	0	0	0	0	0
Ordinary shares, 0.001 par value per share, 10,000 shares authorized	6,608	6,734	6,838	6,937	7,043
Accumulated other comprehensive income (loss)	5	−162	11	−27	36
Retained earnings (accumulated deficit)	−3,678	−2,252	−2,080	−2,068	−1,927
Total shareholders equity	2,936	4,319	4,768	4,842	5,152
Total liabilities and shareholders' equity	8,535	9,648	10,809	11,017	10,426
Preferred shares, issued (in shares)	0	0	0	0	0
Preferred shares, outstanding (in shares)	0	0	0	0	—
Ordinary shares, issued (in shares)	138	137	136	135	134
Ordinary shares, outstanding (in shares)	138	137	136	135	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	338	326	360	339	312
Share-based compensation	55	64	69	55	60
Restructuring charges	67	100	41	43	—
Settlement of interest rate derivatives	0	41	0	0	—
Amortization of debt discount	9	9	2	−700,000	−4
Gain (loss) on sale of business	2	−6	0	1	−48
Gain on sale of assets	0	−28	−4	−5	—
Dedesignation of interest rate swap agreements	0	14	0	0	—
Amortization on hedging instruments	−24	−10	2	—	—
Deferred income taxes	−51	10	−107	−51	9
Other non-cash adjustments, net	7	600,000	24	8	200,000
Subtotal	340	438	464	287	452
Accounts receivable	31	−11	−57	100,000	−160
Inventories	−61	14	19	−77	−2
Prepaid expenses and other current assets	8	20	48	26	0
Accounts payable	−29	54	−66	100	−8
Payroll and related taxes	−63	−94	−53	−38	−53
Accrued customer programs	−26	−26	23	11	—
Other accrued liabilities	−17	−1	7	10	—
Accrued income taxes	56	−32	−13	−48	−48
Other long term liabilities	−200,000	0	8	—	—
Other operating, net	0	2	26	35	−5
Subtotal	−101	−75	−59	20	−295
Net cash from operating activities	239	363	406	307	156
Proceeds from royalty rights	6	5	20	3	—
Asset acquisitions, net	−2	−13	0	0	−71
Settlement of foreign currency derivatives	0	−48	0	62	—
Proceeds from sale of assets	0	38	4	26	—
Additions to property, plant and equipment	−93	−118	−102	−96	−152
Net proceeds from sale of businesses	14	216	0	59	1,492
Other investing, net	−500,000	0	0	0	3
Net cash (for) from investing activities	−75	79	−78	−1,959	1,276
Issuances of long-term debt	0	1,091	295	1,587	0
Payments on long-term debt	−35	−1,529	−325	−971	−31
Payments for debt issuance costs	0	−5	0	−21	0
Cash dividends	−159	−153	−150	−142	−130
Shares used to settle taxes	−19	−16	−19	—	—
Other financing, net	−7	−500,000	12	−20	−19
Net cash for financing activities	−221	−611	−187	422	−179
Effect of exchange rate changes on cash and cash equivalents	33	−23	10	—	—
Net (decrease) increase in cash and cash equivalents	−25	−193	151	−1,279	1,238
Interest paid	202	251	277	217	133
Interest received	60	75	101	58	8
Income taxes paid	99	156	108	100	448
Income taxes refunded	20	3	11	3	17

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro